Results 111 to 120 of about 43,190 (248)

Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial.

European Heart Journal, 2019
AIMS To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban.
Stefano Barco, I. Schmidtmann, W. Ageno, R. Bauersachs, C. Becattini, E. Bernardi, J. Beyer-Westendorf, L. Bonacchini, J. Brachmann, M. Christ, M. Czihal, D. Duerschmied, K. Empen, C. Espinola-Klein, J. Ficker, C. Fonseca, S. Genth‐Zotz, D. Jiménez, V. Harjola, M. Held, Lorenzo Iogna Prat, T. Lange, A. Manolis, A. Meyer, P. Mustonen, U. Rauch-Kroehnert, P. Ruiz-Artacho, S. Schellong, M. Schwaiblmair, R. Stahrenberg, P. Westerweel, P. Wild, S. Konstantinides, M. Lankeit   +33 more
semanticscholar   +1 more source

Wound, pressure ulcer, and burn guidelines (2023)―4: Guidelines for the management of connective tissue disease/vasculitis‐associated skin ulcers, third edition

The Journal of Dermatology, EarlyView.
Yoshihide Asano, Jun Asai, Takayuki Ishii, Yohei Iwata, Masanari Kodera, Chie Miyabe, Akihiko Uchiyama, Youichi Ogawa, Ken Okamura, Mari Kishibe, Yuta Koike, Yorihisa Kotobuki, Noriki Fujimoto, Takuya Miyagi, Yukie Yamaguchi, Ayumi Yoshizaki, Reiko Omori, Takeshi Nakanishi, Hiroshi Fujiwara, Takeo Maekawa, Sei‐ichiro Motegi, Yuichiro Yoshino, Minoru Hasegawa, Manabu Fujimoto, Takao Tachibana, Wound, Pressure Ulcer, and Burn Guidelines Drafting Committee (connective tissue disease/vasculitis group)   +27 more
wiley   +1 more source

Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction There are important challenges with the measurement and interpretation of direct oral anticoagulant (DOAC) anticoagulant effect including a lack of therapeutic ranges, inaccuracy of routinely available coagulation assays, lack of established thresholds for clinically significant effect, and uncertainty about how to apply the ...
Siraj Mithoowani, Chee Wee Tan, Deborah M. Siegal   +2 more
wiley   +1 more source

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation

Therapeutics and Clinical Risk Management, 2014
Alexander GG Turpie Department of Medicine, McMaster University, Hamilton, ONT, Canada Abstract: Atrial fibrillation (AF) is the most common cardiac arrhythmia in the developed world and is associated with a fivefold increase in the risk of stroke ...
Turpie AGG
doaj  

Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries.

PLoS ONE
BackgroundThe European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on rivaroxaban or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine clinical practice ...
Ana Ruigómez, Tania Schink, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin Swart-Polinder, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis Alberto García Rodríguez   +9 more
doaj   +1 more source

Water Vapor Energy Therapy Safely Reduces Urinary Medication Use: A Multicenter Retrospective Real‐World Study in Japan (SCCOP Study 24‐01)

International Journal of Urology, EarlyView.
ABSTRACT Objective The Japanese guidelines for male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) recommend the water vapor energy therapy (WAVE) procedure only for patients in whom conventional BPH surgery is unsuitable due to advanced age or comorbidities.
Junya Abe, Yuki Kyoda, Kazunori Haga, Takumi Sasao, Daito Nishiyama, Seisuke Nofuji, Koji Ichihara, Yohei Matsuda, Tomohiro Toyota, Yohei Ueki, Shuto Konta, Sho Nakayama, Jurai Shibuya, Genki Kobayashi, Takeshi Maehana, Yusuke Nakajima, Naoya Masumori   +16 more
wiley   +1 more source

Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen [PDF]

, 2006
Dagmar Kubitza, Michael Becka, Wolfgang Mueck, Michael Zuehlsdorf   +3 more
openalex   +1 more source

Efficacy of pro‐haemostatic agents in the management of factor Xa inhibitor‐associated intracranial haemorrhages

Internal Medicine Journal, EarlyView.
Abstract Background An increasing number of patients in Australia are taking direct oral anticoagulants for a variety of indications since their introduction in the treatment landscape. There has always been some concern about the optimal management approach in the setting of major and/or life‐threatening bleeding.
Sara Shu‐Ling Ng, Hashim Noori, Diem Nguyen, Zhengbang Wang, Danny Hsu   +4 more
wiley   +1 more source

A comparative study of the clinical benefits of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation with high bleeding risk

Frontiers in Cardiovascular Medicine
ObjectiveRivaroxaban and dabigatran are approved to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF). However, the clinical benefits of rivaroxaban and dabigatran in people with high bleeding risk are unclear.MethodsA ...
Penghui Liu
doaj   +1 more source

A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement [PDF]

, 2006
Bengt I. Eriksson, Lars C. Borris, Ola E. Dahl, Sylvia Haas, Menno V. Huisman, Ajay K. Kakkar, Eva Muehlhofer, Christoph Dierig, Frank Misselwitz, Peter Kälebo   +9 more
openalex   +1 more source